CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc....
Antimicrobial
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists...
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
BOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
Cosmos Health Continues to Expand Mediterranation Brand, Welcomes Eleonas and Olympus Mons; Boosts Exports and Secures Purchase Orders, Including from Leading Multinational Health Food Chain
CHICAGO, IL / ACCESSWIRE / August 2, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global...
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the...
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing...
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30...
Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing...
Fortifeye Vitamins Unveils the Cutting-Edge, Next Gen, Zinc-Free Macular Defense Formula, Elevating Eye Health to New Heights
Fortifeye Vitamins Releases Next Gen, Zinc-Free Macular DefenseOCALA, FL / ACCESSWIRE / July 28, 2023 / Fortifeye Vitamins, a pioneering...
T2 Biosystems to Attend Upcoming Investor Conferences
LEXINGTON, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Pressure BioSciences Launches Program to Evaluate Company’s Patented UltraShear Process in Breakthrough Application to Extend Shelf-Life of Fresh Produce
Scientific Publications Demonstrate Effectiveness of CBD and Essential Oil Nanoemulsions in Shelf-Life Extension of Fruits and Vegetables; PBI Initiating Studies...
Fortifeye Vitamins Breaks New Ground With Next Gen Zinc-Free Macular Degeneration Formula
Fortifeye Vitamins Introduces Next Gen Zinc-Free Macular DefenseOCALA, FL / ACCESSWIRE / July 25, 2023 / Fortifeye Vitamins, a leading...
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.Lyon...
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
Received record quarterly sepsis test panel orders and strengthened balance sheetLEXINGTON, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems,...
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review statusLOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE®...
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes
Breakthrough in diagnostics testing enables ‘facial recognition for germs’ Collaboration with John Radcliffe Hospital used AI to identify respiratory viruses...
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement...
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...